AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00869882 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral fusion with instrumentation
Description: Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~* Central stenosis: decompression is performed including medial facectomy, laminectomy;~* Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~* Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed.
Study NCT02826369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3.0 Tesla in Magnetic Resonance Imaging
Description: Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition.
Study NCT04145037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVR-RD-02
Description: AVR-RD-02 Drug product: active substance is autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified ex vivo with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase).
Study NCT03070509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: lisdexamfetamine 50 mg single dose
Study NCT02772575 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic trans-arterial embolization (TAE)
Study NCT02772575 — intervention group
Intervention type: DEVICE
Intervention: MRI/CT scan
Study NCT02772575 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy
Study NCT02772575 — intervention group
Intervention type: OTHER
Intervention: blood draw
Study NCT02909036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02909036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study NCT02909036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Progenitor Cell Transplant
Study NCT01191060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib
Description: Lenalidomide/Bortézomib/Dexamethasone cycles:~Number of cycles: 8 cycles for arm A~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed
Study NCT01191060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib
Description: Lenalidomide Bortezomib Dexamethasone cycles:~Number of cycles: 5 cycles for arm B~Cycle length~Dosage:~* Lenalidomide: 25 mg/day on days 1-14 of each cycle~* Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed
Study NCT00525265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061(Tolvaptan)
Description: Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
Study NCT00525265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be orally administered placebo once daily after breakfast for seven days.
Study NCT00073827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol tartrate MDI
Description: levalbuterol 90 mcg QID
Study NCT00073827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic albuterol MDI
Description: racemic albuterol 180 mcg QID
Study NCT00073827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI QID
Study NCT03555630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastogram
Description: Blood sample processing for thromboelastogram
Study NCT02206022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Pain's evaluation for Remifentanil Group
Study NCT02206022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CVC pain's evaluation after local anesthesia + placebo infusion
Study NCT03491423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short and fast step test without measurement of pulmonary gas exchange
Description: For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
Study NCT03491423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: glucose meter
Description: glucose meter to measure lactatemia
Study NCT03491423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECG / heart rate
Description: ECG and heart rate (HR) collection by telemetry
Study NCT03491423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: VAS pain assessment and evaluation of effort perception according to Borg's scale
Study NCT03491423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short and fast step test with measurement of pulmonary gas exchange
Description: For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
Study NCT02118337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0680
Description: Participants will receive IV infusion of MEDI0680 0.1 or 0.5 or 2.5 or 10 or 20 mg/kg Q2W in dose-escalation phase and 20 mg/kg Q2W in dose-expansion phase.
Study NCT02118337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab 3 and 10 mg Q2W in dose-escalation phase and 750 mg Q2W in dose-expansion phase.
Study NCT02118337 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Participants will receive IV infusion of nivolumab 240 mg Q2W in dose-expansion phase.
Study NCT01533571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implant placement with simultaneous bone grafting
Description: * Flapless surgery is used for surgical implant installation.~* Implant is placed in the cingulum position of adjacent teeth incisal edge.~* After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.~* Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .~Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material.
Study NCT02218528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based ingredient
Study NCT02218528 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Plant-based ingredient
Study NCT03331133 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT04084977 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Antibody detection
Description: detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside
Study NCT03748017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control Supplement
Description: A once-daily oral dose of the placebo-control supplement will be consumed by adults for 14 consecutive days.
Study NCT03748017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus-Containing Probiotic Supplement
Description: A once-daily oral dose of the streptococcus-containing probiotic supplement will be consumed by adults for 14 consecutive days.
Study NCT04169711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-HIF2
Description: Multiple doses of ARO-HIF2 by intravenous infusion
Study NCT03332641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citron peel extract
Description: Citron peel extract for 12 weeks
Study NCT03332641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study NCT03735563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Individuals will receive randomly either ketamine or fentanyl as a premedication
Study NCT03735563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Individuals will receive randomly either ketamine or fentanyl as a premedication
Study NCT01515189 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02746042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinupret extract coated tablets
Description: 1 coated tablet 3 times a day for 16-weeks (1-1-1)
Study NCT02746042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo coated tablets
Description: 1 coated tablet 3 times a day for 16-weeks (1-1-1)
Study NCT03733743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized living protocol
Description: Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
Study NCT04548271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Anti-PD-1 targeted immunotherapy
Study NCT04548271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: A small-molecule vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor
Study NCT03676920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussions of Cost App (DISCO App)
Description: The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
Study NCT00581633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal saline (0.9%)
Description: liter normal saline over 30 minutes x 1 dose
Study NCT05482737 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This is an observational retrospective study (meta-analysis)
Study NCT02798276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AGTP-treatment
Description: Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
Study NCT02798276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
Study NCT04341415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular neuromodulation
Description: The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile neuromodulation needle placement (service protocol with Chlorhexidine) Placement of 4 semi-permanent Classic needles (SEDATELEC®) on each ear flap at the level of the concha (innervated by the vagus nerve) according to an order and a precise location (4 cardinal points conch), i.e. 8 needles per patient.~Compress soaked with Oxygenated water on the concha (to stop potential bleeding).~Placing an opaque dressing on the ear and a non-occlusive Band-Aid
Study NCT04341415 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The pose is carried out by the principal investigator, alone, without the presence of the nursing staff in the room.~Ear disinfection and sterile manipulation without needle placement (service protocol with Chlorhexidine) No needle laying but only sterile disinfection and pressure over the 4 putative locations with the sterile plastic tip (without the needle).~Compress soaked with Oxygenated water on the concha. Placing an opaque dressing on the ear and a non-occlusive Band-Aid.
Study NCT02391545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: PI3K Inhibitor
Study NCT02391545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: monoclonal antibody
Study NCT02391545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: monoclonal antibody
Study NCT02924558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg protein/unsaturated fatty acid
Description: Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
Study NCT02924558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
Study NCT02968121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole, OPDC-34712
Study NCT04978545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calciumhydroxide, intracanal medicament
Description: In the CH group, calcium hydroxide powder (Calxyl; OCO Products, Dirnstein, Germany) was mixed with saline in a ratio 1:1 and the paste was inserted into the canal by using lentulo spirals (Malleifer-Dentsply).
Study NCT04978545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine, intracanal medicament
Description: , chlorhexidine gel 2% (Gluco-Chex 2% gel, Cerkamed, Stalowa Wola, Polland) was placed into the root canals of this group with an Ultradent Capillary Tip (Ultradent products).
Study NCT03622879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MT
Description: A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
Study NCT03622879 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: MT
Description: A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
Study NCT03622879 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
Study NCT03622879 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
Study NCT03622879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower-limb task-oriented training
Description: The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
Study NCT03622879 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lower-limb task-oriented training
Description: The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
Study NCT03622879 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lower-limb task-oriented training
Description: The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
Study NCT03312686 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: endoflip
Description: Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
Study NCT02917577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avaxim Pediatric®
Description: 2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
Study NCT02917577 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avaxim ® (adult)
Description: 2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
Study NCT03780374 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Audéo L2M with Sound Processing Principle 1
Description: Compensation of a hearing loss with Sound Processing Principle 1.
Study NCT03780374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audéo L2M with Sound Processing Principle 2
Description: Compensation of a hearing loss with Sound Processing Principle 2.
Study NCT03780374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audéo L2M with Sound Processing Principle 3
Description: Compensation of a hearing loss with Sound Processing Principle 3.
Study NCT02579356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT02579356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT00702416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous interscalene brachial plexus block
Description: With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.~A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.~At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots.
Study NCT00702416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous interscalene brachial plexus block using electrical nerve stimulation
Description: With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.~A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.~An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought~Injection of the local anesthetic will start with a visible motor response at a current \<0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA.
Study NCT00702416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Block induction \[1% (wt/vol) solution\]:~20 ml (200 mg)~Postoperative analgesia \[0.2% (wt/vol) solution\]:~* Background infusion: 4 ml/h (8 mg/h)~* Incremental on-demand dose: 2 ml (4 mg)~* Lockout time: 15 min
Study NCT00702416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Block induction \[1% (wt/vol) solution\]:~20 ml (200 mg)~Postoperative analgesia \[0.2% (wt/vol) solution\]:~* Background infusion: 4 ml/h (8 mg/h)~* Incremental on-demand dose: 2 ml (4 mg)~* Lockout time: 15 min
Study NCT00702416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1 g iv q8h
Study NCT00702416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1 g iv q8h
Study NCT00702416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 5 mg im prn q1h (in the postoperative period)